A new antithrombotic agent with no effect on bleeding

  • There is an need to develop safer and more effective treatments to prevent bleeding in patients undergoing anticoagulation therapy.

  • A novel target to prevent thrombus formation has been identified (from biobank and patients data).

  • Target validation: 

    • Chemical probes identified 

    • In vivo proof of concept using three different thrombosis models 

    • Safety: minimal bleeding risk and no effect on coagulation

  • Primary indication: Patients in high risk of blleding undergoing anticoagulant therapy.

>> Download more information

New treatment in heart failure: a novel antifibrotic target Lead optimization stage

  • Heart Failure (HF) is a chronic, progressive condition in which the heart muscle is unable to pump sufficient quantity of blood through the arterial system to meet the body's needs for blood and oxygen.

  • There is an unmet need to develop new antifibrotic therapies to treat HF since fibrosis is present even in the heart of those HF patients treated according to the current clinical practice guidelines, and it is associated with a bad prognosis.

  • A novel target to treat myocardial fibrosis in HF has been identified (from biobank and patients data).

    • It is over‐stimulated in the myocardium of HF patients

    • There is a related biomarker measurable in blood

    • A proof of concept has been developed: siRNA and chemical probe.

  • Primary Indication: Heart Failure.


Contacta con nosotros

Centro de Investigación Médica Aplicada (CIMA)
Avenida Pío XII, 55
31008 Pamplona

+34 948 194 700